Viewing Study NCT00062504



Ignite Creation Date: 2024-05-05 @ 11:30 AM
Last Modification Date: 2024-10-26 @ 9:08 AM
Study NCT ID: NCT00062504
Status: TERMINATED
Last Update Posted: 2011-05-23
First Post: 2003-06-06

Brief Title: Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas
Sponsor: Teva Branded Pharmaceutical Products RD Inc
Organization: Teva Branded Pharmaceutical Products RD Inc

Study Overview

Official Title: A Phase II Trial of Talampanel in Patients With Recurrent High-Grade Gliomas
Status: TERMINATED
Status Verified Date: 2011-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To analyze the effect of Talampanel on progression free survival in patients with recurrent high grade gliomas
Detailed Description: To determine the efficacy of Talampanel in patients with recurrent malignant glioma as measured by 6-month progression survival as well as to obtain preliminary information regarding the spectrum of toxicities of the drug among this patient population

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None